Migratory potential of transplanted glial progenitors as critical factor for successful translation of glia replacement therapy

The gap between mice and men

Rohit K. Srivastava, Jeff W Bulte, Piotr Walczak, Miroslaw Janowski

Research output: Contribution to journalReview article

Abstract

Neurological disorders are a major threat to public health. Stem cell-based regenerative medicine is now a promising experimental paradigm for its treatment, as shown in pre-clinical animal studies. Initial attempts have been on the replacement of neuronal cells only, but glial progenitors (GPs) are now becoming strong alternative cellular therapeutic candidates to replace oligodendrocytes and astrocytes as knowledge accumulates about their important emerging role in various disease processes. There are many examples of successful therapeutic outcomes for transplanted GPs in small animal models, but clinical translation has proved to be challenging due to the 1,000-fold larger volume of the human brain compared to mice. Human GPs transplanted into the mouse brain migrate extensively and can induce global cell replacement, but a similar extent of migration in the human brain would only allow for local rather than global cell replacement. We review here the mechanisms that govern cell migration, which could potentially be exploited to enhance the migratory properties of GPs through cell engineering pre-transplantation. We furthermore discuss the (dis)advantages of the various cell delivery routes that are available, with particular emphasis on intra-arterial injection as the most suitable route for achieving global cell distribution in the larger brain. Now that therapeutic success has proven to be feasible in small animal models, future efforts will need to be directed to enhance global cell delivery and migration to make bench-to-bedside translation a reality.

Original languageEnglish (US)
Pages (from-to)907-919
Number of pages13
JournalGLIA
Volume66
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Neuroglia
Brain
Cell Movement
Stem Cells
Animal Models
Cell Engineering
Intra-Arterial Injections
Regenerative Medicine
Oligodendroglia
Therapeutics
Nervous System Diseases
Astrocytes
Public Health
Transplantation

Keywords

  • glial progenitors
  • migration
  • myelin
  • neurological disorder
  • transplantation

ASJC Scopus subject areas

  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Migratory potential of transplanted glial progenitors as critical factor for successful translation of glia replacement therapy : The gap between mice and men. / Srivastava, Rohit K.; Bulte, Jeff W; Walczak, Piotr; Janowski, Miroslaw.

In: GLIA, Vol. 66, No. 5, 01.05.2018, p. 907-919.

Research output: Contribution to journalReview article

@article{1a3972122270475882ffccf98894e892,
title = "Migratory potential of transplanted glial progenitors as critical factor for successful translation of glia replacement therapy: The gap between mice and men",
abstract = "Neurological disorders are a major threat to public health. Stem cell-based regenerative medicine is now a promising experimental paradigm for its treatment, as shown in pre-clinical animal studies. Initial attempts have been on the replacement of neuronal cells only, but glial progenitors (GPs) are now becoming strong alternative cellular therapeutic candidates to replace oligodendrocytes and astrocytes as knowledge accumulates about their important emerging role in various disease processes. There are many examples of successful therapeutic outcomes for transplanted GPs in small animal models, but clinical translation has proved to be challenging due to the 1,000-fold larger volume of the human brain compared to mice. Human GPs transplanted into the mouse brain migrate extensively and can induce global cell replacement, but a similar extent of migration in the human brain would only allow for local rather than global cell replacement. We review here the mechanisms that govern cell migration, which could potentially be exploited to enhance the migratory properties of GPs through cell engineering pre-transplantation. We furthermore discuss the (dis)advantages of the various cell delivery routes that are available, with particular emphasis on intra-arterial injection as the most suitable route for achieving global cell distribution in the larger brain. Now that therapeutic success has proven to be feasible in small animal models, future efforts will need to be directed to enhance global cell delivery and migration to make bench-to-bedside translation a reality.",
keywords = "glial progenitors, migration, myelin, neurological disorder, transplantation",
author = "Srivastava, {Rohit K.} and Bulte, {Jeff W} and Piotr Walczak and Miroslaw Janowski",
year = "2018",
month = "5",
day = "1",
doi = "10.1002/glia.23275",
language = "English (US)",
volume = "66",
pages = "907--919",
journal = "GLIA",
issn = "0894-1491",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Migratory potential of transplanted glial progenitors as critical factor for successful translation of glia replacement therapy

T2 - The gap between mice and men

AU - Srivastava, Rohit K.

AU - Bulte, Jeff W

AU - Walczak, Piotr

AU - Janowski, Miroslaw

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Neurological disorders are a major threat to public health. Stem cell-based regenerative medicine is now a promising experimental paradigm for its treatment, as shown in pre-clinical animal studies. Initial attempts have been on the replacement of neuronal cells only, but glial progenitors (GPs) are now becoming strong alternative cellular therapeutic candidates to replace oligodendrocytes and astrocytes as knowledge accumulates about their important emerging role in various disease processes. There are many examples of successful therapeutic outcomes for transplanted GPs in small animal models, but clinical translation has proved to be challenging due to the 1,000-fold larger volume of the human brain compared to mice. Human GPs transplanted into the mouse brain migrate extensively and can induce global cell replacement, but a similar extent of migration in the human brain would only allow for local rather than global cell replacement. We review here the mechanisms that govern cell migration, which could potentially be exploited to enhance the migratory properties of GPs through cell engineering pre-transplantation. We furthermore discuss the (dis)advantages of the various cell delivery routes that are available, with particular emphasis on intra-arterial injection as the most suitable route for achieving global cell distribution in the larger brain. Now that therapeutic success has proven to be feasible in small animal models, future efforts will need to be directed to enhance global cell delivery and migration to make bench-to-bedside translation a reality.

AB - Neurological disorders are a major threat to public health. Stem cell-based regenerative medicine is now a promising experimental paradigm for its treatment, as shown in pre-clinical animal studies. Initial attempts have been on the replacement of neuronal cells only, but glial progenitors (GPs) are now becoming strong alternative cellular therapeutic candidates to replace oligodendrocytes and astrocytes as knowledge accumulates about their important emerging role in various disease processes. There are many examples of successful therapeutic outcomes for transplanted GPs in small animal models, but clinical translation has proved to be challenging due to the 1,000-fold larger volume of the human brain compared to mice. Human GPs transplanted into the mouse brain migrate extensively and can induce global cell replacement, but a similar extent of migration in the human brain would only allow for local rather than global cell replacement. We review here the mechanisms that govern cell migration, which could potentially be exploited to enhance the migratory properties of GPs through cell engineering pre-transplantation. We furthermore discuss the (dis)advantages of the various cell delivery routes that are available, with particular emphasis on intra-arterial injection as the most suitable route for achieving global cell distribution in the larger brain. Now that therapeutic success has proven to be feasible in small animal models, future efforts will need to be directed to enhance global cell delivery and migration to make bench-to-bedside translation a reality.

KW - glial progenitors

KW - migration

KW - myelin

KW - neurological disorder

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=85043684493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043684493&partnerID=8YFLogxK

U2 - 10.1002/glia.23275

DO - 10.1002/glia.23275

M3 - Review article

VL - 66

SP - 907

EP - 919

JO - GLIA

JF - GLIA

SN - 0894-1491

IS - 5

ER -